Local Coverage DeterminationGastroenterology

LCD L37299: MolDX: Prometheus® IBD sgi Diagnostic® Policy — Noridian

LCD-L37299

Document details

Document type: Local Coverage Determination
Issuing body: MAC Contractor
Document ID: LCD-L37299
Published: June 5, 2026
Effective date: February 5, 2026
MAC region: Noridian

Summary

The implementation of the Prometheus® IBD sgi Diagnostic® policy by Noridian is set to impact billing procedures starting February 5, 2026. Providers will need to ensure compliance with the latest gui

New billing policy effective February 2026 for IBD diagnostics.

Affected codes

ICD-10-CM

L37299

Affected specialty

Gastroenterology alerts →

Source document

https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37299&ver=30

CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.

Related alerts

FDA Approval: TERLIVAZ (TERLIPRESSIN) — Type 1 - New Molecular Entity

Policy FDA-NDA022231 · Gastroenterology

High

Terlivaz (terlipressin) is an injectable medication, likely to receive an assigned J-code for billing under Medicare Part B. Given its status as an orphan drug, it may qualify for pass-through payment

View alert

Proposed LCD DL38571: Colon Capsule Endoscopy (CCE) — NGS

Policy LCD-DL38571 · Gastroenterology

High

The proposed LCD for Colon Capsule Endoscopy (CCE) may lead to increased compliance updates for gastroenterology practices, as it could allow for reimbursement for procedures that were previously n

View alert

Proposed LCD DL40187: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — Palmetto GBA

Policy LCD-DL40187 · Gastroenterology

High

The proposed LCD for biomarker testing aims to clarify coverage criteria for metabolic dysfunction-associated conditions, potentially increasing access for necessary testing. This may lead to improved

View alert

Proposed LCD DL40272: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — WPS

Policy LCD-DL40272 · Gastroenterology

High

The proposed LCD for biomarker testing in metabolic liver disease may affect reimbursement practices by clarifying coverage policies which could lead to increased utilization of these tests. Providers

View alert